FORA Capital LLC Purchases Shares of 12,624 Omnicell, Inc. (NASDAQ:OMCL)

FORA Capital LLC purchased a new stake in Omnicell, Inc. (NASDAQ:OMCL) during the first quarter, according to its most recent filing with the SEC. The fund purchased 12,624 shares of the company’s stock, valued at approximately $369,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of OMCL. Neo Ivy Capital Management purchased a new position in shares of Omnicell in the 3rd quarter worth $78,000. Benjamin Edwards Inc. grew its stake in shares of Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after buying an additional 868 shares in the last quarter. Strs Ohio grew its stake in shares of Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock worth $188,000 after buying an additional 1,100 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of Omnicell in the 3rd quarter worth $200,000. Finally, Aristides Capital LLC purchased a new position in shares of Omnicell in the 4th quarter worth $269,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Down 1.8 %

Omnicell stock traded down $0.47 during trading hours on Tuesday, hitting $25.82. The company had a trading volume of 115,416 shares, compared to its average volume of 519,535. The firm has a market cap of $1.19 billion, a P/E ratio of -56.54, a P/E/G ratio of 94.22 and a beta of 0.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.13 and a current ratio of 2.38. Omnicell, Inc. has a 1 year low of $25.45 and a 1 year high of $75.07. The company has a 50-day moving average price of $29.30 and a two-hundred day moving average price of $29.96.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.17. Omnicell had a negative net margin of 1.91% and a positive return on equity of 2.41%. The business had revenue of $246.15 million during the quarter, compared to analyst estimates of $235.70 million. On average, sell-side analysts anticipate that Omnicell, Inc. will post 0.2 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on OMCL shares. StockNews.com raised shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Monday. Benchmark reaffirmed a “buy” rating and set a $38.00 price target on shares of Omnicell in a research note on Tuesday, April 30th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Omnicell has a consensus rating of “Hold” and an average target price of $42.20.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.